Aligos Therapeutics, Inc. Stock Price, News & Analysis

Aligos Therapeutics (Nasdaq: ALGS) announced the acceptance of four abstracts for presentation at The Liver Meeting (TLM) 2024, hosted by the American Association for the Study of Liver Disease (AASLD) from November 15-19, 2024 in San Diego. The presentations include:

1. A late-breaker oral presentation on ALG-055009, a potential best-in-class THR-β agonist for Metabolic Dysfunction-Associated Steatohepatitis (MASH), showcasing Phase 2a HERALD study results.

2. Three poster presentations: two on ALG-000184, a potential first-/best-in-class CAM-E for chronic hepatitis B (CHB), and one on the nonclinical toxicology profile of ALG-055009.

The abstracts highlight promising results for both drug candidates, including high viral suppression rates for ALG-000184 in CHB patients and significant liver fat reductions for ALG-055009 in MASH patients.

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company focusing on liver and viral diseases, has announced the granting of non-qualified stock options to newly hired employees. The Compensation Committee of the Company's Board of Directors approved these Inducement Grants on October 8, 2024, totaling 95,000 shares of the Company's stock.

Notably, Dr. Hardean Achneck, the new Chief Medical Officer, received an option to purchase 75,000 shares. These grants, made under Aligos' 2024 Employment Inducement Award Plan, comply with Nasdaq Listing Rule 5635(c)(4) and serve as an inducement for new employees. The options have an exercise price equal to the closing price of Aligos' common stock on the grant date and will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, subject to continued employment.

Aligos Therapeutics (Nasdaq: ALGS) has appointed David Perry as Vice President of Business Development, effective immediately. Perry brings over 20 years of experience in the life sciences industry, with expertise in corporate strategy, business development, and investment management. His most recent role was Senior Director of Business Development at Sangamo Therapeutics, where he led a significant licensing deal with Genentech.

Prior to Sangamo, Perry served as Senior Director and Head of Business Development at Apexigen Inc., where he played a key role in the company's acquisition by Pyxis Oncology. Aligos' Executive VP and CFO, Lesley Ann Calhoun, expressed confidence that Perry's expertise in leading valuable partnerships will be important in maximizing the potential of Aligos' pipeline, including ALG-055009, which recently reported positive topline data.

Aligos Therapeutics, a clinical stage biopharmaceutical company focused on liver and viral diseases, has announced its participation in two upcoming investor conferences in October. The company will be featured in fireside chats at the following events:

1. H.C. Wainwright 8th Annual MASH Virtual Conference on October 7, 2024, at 3:00pm ET/12:00pm PT

2. H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on October 8, 2024, at 3:00pm ET/12:00pm PT

Both events will be webcast live and can be accessed through the Presentation & Events section on the Investors page of Aligos' website. Replays will be available for at least 30 days following the presentations.

Aligos Therapeutics (Nasdaq: ALGS) has appointed Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck, a seasoned clinical development executive with expertise in hepatology and infectious diseases, will lead the company's global clinical development efforts and join the Senior Leadership Team. This appointment follows Aligos' recent positive topline data for ALG-055009 in MASH subjects.

Dr. Achneck brings extensive experience from previous roles, including Senior Vice President and Head of Clinical Development at Pliant Therapeutics, and Vice President of Clinical Development and Clinical Research at Dicerna Therapeutics. He has successfully advanced liver-targeted oligonucleotide assets and has a strong background in hepatic diseases. Dr. Achneck holds an M.D. from Yale University School of Medicine and is licensed to practice medicine in the U.S. and EU.

Aligos Therapeutics (Nasdaq: ALGS) announced positive topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta agonist, for treating metabolic-dysfunction associated steatohepatitis (MASH). The study met its primary endpoint with statistically significant reductions in liver fat at Week 12, measured by MRI-PDFF. Key findings include:

1. Placebo-adjusted median relative reductions in liver fat up to 46.2% with a clear dose response
2. ALG-055009 was well-tolerated with no serious adverse events
3. Significant reductions in atherogenic lipids, including LDL-C, lipoprotein (a), and apolipoprotein B
4. Up to 70% of subjects achieved ≥30% relative reduction in liver fat compared to baseline

The company is evaluating options for further development, including potential partnerships.

Aligos Therapeutics (Nasdaq: ALGS) is set to announce topline results from its Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist for the treatment of metabolic-dysfunction associated steatohepatitis (MASH), on September 19, 2024. The company, focused on developing therapies for liver and viral diseases, will release the results before market open and host a conference call and webcast at 8:30am ET/5:30am PT to discuss the findings.

Investors and interested parties can access the live webcast with slides on the Aligos website's Presentation & Events page. A replay of the webcast will be available for 90 days following the live presentation.

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral diseases, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The company's Compensation Committee granted a non-qualified stock option to purchase 3,500 shares to a newly hired employee on September 10, 2024. This grant, made under Aligos' 2024 Inducement Plan, serves as an inducement for employment.

The stock option's exercise price equals the closing price of Aligos' common stock on the grant date. The shares will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments, contingent on continued employment.

Aligos Therapeutics (Nasdaq: ALGS) has announced a 1-for-25 reverse stock split effective August 19, 2024. The company's common stock will continue trading on the Nasdaq Capital Market under the same symbol with a new CUSIP number. This move primarily aims to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The reverse split will affect all outstanding stock options, warrants, and equity incentive plans proportionally. No fractional shares will be issued, with stockholders receiving cash payments instead. The split was approved by stockholders on June 27, 2024, and subsequently by the Board of Directors. Continental Stock Transfer & Trust Company is acting as the exchange and transfer agent for the process.